• 1. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 2. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 3. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

Methyl 3,5-difluoroisonicotinate (CAS No. 1214324-60-3): A Key Intermediate in Modern Pharmaceutical Synthesis

Methyl 3,5-difluoroisonicotinate (CAS No. 1214324-60-3) is a fluorinated derivative of isonicotinic acid, representing a significant intermediate in the synthesis of various pharmaceutical compounds. Its unique structural features, particularly the presence of fluorine atoms at the 3rd and 5th positions of the pyridine ring, contribute to its utility in medicinal chemistry and drug development. This compound has garnered considerable attention due to its role in producing bioactive molecules with enhanced metabolic stability and improved pharmacokinetic properties.

The introduction of fluorine atoms into organic molecules is a well-established strategy in pharmaceutical design, leveraging the element's ability to modulate molecular properties such as lipophilicity, binding affinity, and metabolic resistance. In the case of Methyl 3,5-difluoroisonicotinate, the electron-withdrawing nature of fluorine exerts a stabilizing influence on the adjacent carboxyl group, facilitating its incorporation into more complex scaffolds. This characteristic makes it particularly valuable for constructing heterocyclic compounds that exhibit promising biological activities.

Recent advancements in synthetic methodologies have further highlighted the versatility of Methyl 3,5-difluoroisonicotinate as a building block. Researchers have demonstrated its efficacy in constructing novel pyridine-based analogs with potential applications in treating infectious diseases and cancer. For instance, studies have shown that derivatives of this compound exhibit inhibitory effects against bacterial enzymes by mimicking natural substrates with enhanced binding affinity. Such findings underscore the importance of fluorinated isonicotinates in developing next-generation antibiotics and antiviral agents.

The role of fluorine in modulating pharmacokinetic profiles has been extensively explored in clinical drug development. Methyl 3,5-difluoroisonicotinate serves as a precursor for synthesizing prodrugs that exhibit prolonged circulation times and reduced susceptibility to enzymatic degradation. This attribute is particularly relevant in the design of anticoagulants and anti-inflammatory drugs, where sustained activity is often desired. Moreover, the incorporation of fluorine into drug candidates has been linked to improved oral bioavailability, a critical factor in therapeutic efficacy.

In parallel with its pharmaceutical applications, Methyl 3,5-difluoroisonicotinate has found utility in agrochemical research. Fluorinated pyridines are known to enhance the stability and performance of pesticides and herbicides, making them more resistant to environmental degradation. By serving as a key intermediate, this compound enables the synthesis of novel agrochemicals that offer higher efficacy while minimizing ecological impact. Such developments align with global efforts to promote sustainable agricultural practices.

The synthesis of Methyl 3,5-difluoroisonicotinate typically involves multi-step reactions starting from commercially available precursors such as ethyl acetoacetate or malononitrile derivatives. Advanced catalytic systems have been developed to streamline these processes while maintaining high yields and purity standards. The use of transition metal catalysts has further facilitated the introduction of fluorine atoms through cross-coupling reactions, providing chemists with greater control over regioselectivity and functional group compatibility.

The growing demand for fluorinated compounds has spurred innovation in fluorination techniques. Methods such as electrophilic aromatic substitution and metal-catalyzed hydrogenation now allow for precise functionalization at specific positions within the pyridine ring. These advancements have enabled researchers to fine-tune the properties of Methyl 3,5-difluoroisonicotinate derivatives to meet specific therapeutic requirements. For example, variations in fluorine substitution patterns can significantly alter binding interactions with biological targets, offering opportunities for structure-activity relationship studies.

Ongoing research continues to uncover new applications for Methyl 3,5-difluoroisonicotinate beyond traditional pharmaceuticals. Its role as a scaffold for developing photoactive compounds has recently gained traction due to the unique electronic properties conferred by fluorine atoms. These photoresponsive molecules hold promise for applications in optogenetics and photodynamic therapy, where precise control over light-induced chemical transformations is essential.

The future prospects for Methyl 3,5-difluoroisonicotinate are closely tied to advancements in synthetic chemistry and drug discovery technologies. As computational modeling becomes increasingly sophisticated, researchers can predict the biological activity of novel derivatives with greater accuracy before conducting experimental validation. This synergy between theory and practice accelerates the development pipeline for new therapeutics while reducing costs associated with traditional trial-and-error approaches.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)